NasdaqGS:PAA
NasdaqGS:PAAOil and Gas

Plains All American Pipeline (PAA): Evaluating Current Valuation After Recent Share Price Gains

Plains All American Pipeline (PAA) shares have moved steadily in recent days. After tracking the stock’s performance this month, investors are weighing how its longer-term returns and income growth compare with other midstream energy companies. See our latest analysis for Plains All American Pipeline. Plains All American Pipeline has seen its share price tick up lately, and over the past year the 7.1% total shareholder return highlights a healthy combination of current yield and gradual...
NasdaqCM:BTBT
NasdaqCM:BTBTSoftware

Bit Digital (BTBT): Valuation Insights Following Robust Q3 Results and Strategic Ethereum Staking Pivot

Bit Digital (BTBT) is drawing attention after its third-quarter earnings release. Revenue gains were powered largely by its growing Ethereum staking business and a reported jump in ETH holdings this year. See our latest analysis for Bit Digital. After a surge of interest tied to Bit Digital’s strategy shift and fresh third-quarter numbers, the share price still tells a volatile story. Despite management’s optimism and impressive expansion in Ethereum holdings, the stock is currently trading...
NYSE:ZBH
NYSE:ZBHMedical Equipment

Zimmer Biomet (ZBH): Assessing Valuation After New FDA Clearance for Advanced ROSA Knee System

Zimmer Biomet Holdings (ZBH) has received FDA 510(k) clearance for a new, enhanced version of its ROSA Knee System. This update introduces advanced customization for robotic-assisted knee surgeries and reflects the company’s ongoing innovation push in orthopedic technology. See our latest analysis for Zimmer Biomet Holdings. This FDA clearance arrives as Zimmer Biomet’s share price has staged a sharp rebound, jumping 8.5% in the past week after a difficult stretch that saw a 7.1% drop year to...
NasdaqGS:MNDY
NasdaqGS:MNDYSoftware

monday.com (MNDY): Assessing Valuation After Cautious Outlook Sways Investors Despite Strong Earnings

Monday.com (MNDY) shares pulled back after the company’s latest earnings release, as its conservative outlook for the next quarter overshadowed solid performance numbers. Investors responded swiftly, reflecting caution over the updated guidance. See our latest analysis for monday.com. Even with monday.com’s recent momentum-building partnerships and its expanding reach into high-profile markets, the share price has struggled, dropping 25% over the past month and posting a 1-year total...
NasdaqGS:TMC
NasdaqGS:TMCMetals and Mining

Should TMC the metals' (TMC) Surging Losses Prompt Investors to Revisit Its Financial Trajectory?

TMC the metals company Inc. recently reported results for the third quarter and nine months ended September 30, 2025, revealing a net loss of US$184.52 million for the quarter and US$279.45 million for the year-to-date, both significantly larger than the losses reported for the same periods last year. The year-over-year increase in losses marked a substantial shift and brought renewed focus to the company’s financial trajectory and operational performance. Given the considerable increase in...
NYSE:AHR
NYSE:AHRHealth Care REITs

Equity Offering Could Be a Game Changer for American Healthcare REIT (AHR)

American Healthcare REIT, Inc. recently filed a follow-on equity offering, registering 8,100,000 shares of common stock with income trust features. This move draws attention to the company's capital raising efforts and the potential effects on existing shareholder dilution and future growth strategy. We'll explore how the newly announced equity offering could influence American Healthcare REIT's ability to fund acquisitions and drive portfolio expansion. Find companies with promising cash...
NasdaqGS:INTR
NasdaqGS:INTRBanks

Inter & Co (NasdaqGS:INTR) Valuation in Focus Following Strong Q3 Earnings Growth

Inter & Co (NasdaqGS:INTR) just announced its third-quarter results, drawing attention to solid growth in net income and earnings per share compared to the same period last year. Investors are watching closely as these numbers come in. See our latest analysis for Inter & Co. The upbeat earnings news added to an already impressive run for Inter & Co, with the share price now at $8.46 after climbing more than 100% since the start of the year. This surge, along with a 62.65% one-year total...
NYSE:NEM
NYSE:NEMMetals and Mining

A Fresh Look at Newmont (NEM) Valuation Following Recent Share Price Surge

Newmont (NEM) shares have seen some interesting movement in recent weeks, climbing more than 19% over the past 3 months. Investors are taking note as broader commodity prices and gold demand continue to shape the outlook for the miner. See our latest analysis for Newmont. Momentum has really been building for Newmont lately. After a standout rally, the 90-day share price return sits at 19.2%, while its one-year total shareholder return leaps an impressive 108.9%. The recent surge suggests...
NasdaqGS:ACLX
NasdaqGS:ACLXBiotechs

Assessing Arcellx (ACLX) Valuation Following New CAR-T Therapy Competition from Kelonia Therapeutics

Arcellx (ACLX) shares came under pressure following early-stage trial data from Kelonia Therapeutics. Kelonia's CAR-T therapy KLN-1010 for multiple myeloma showed strong signals of efficacy, raising questions about Arcellx’s competitive positioning. See our latest analysis for Arcellx. With the renewed spotlight on CAR-T therapies, Arcellx shares have come under pressure, dropping nearly 19% over the past week after Kelonia’s new trial data stirred concerns about future competition. While...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Is Intuit Fairly Priced After Latest Product Launches and Five Year 88% Gain?

If you have ever wondered whether Intuit stock is fairly priced or has hidden value, you are not alone, especially with the tech sector constantly in motion. Intuit’s share price has seen some modest movement lately: down 0.4% over the last week, slipping 5.2% in the past month, but still up 4.1% year-to-date and delivering an impressive 88.1% gain over the last five years. Recent headlines have ranged from product launches aimed at expanding Intuit's small business platform to strategic...
NasdaqGS:BLKB
NasdaqGS:BLKBSoftware

Blackbaud (BLKB): Evaluating Valuation as Investors Weigh Recent Share Price Volatility

Blackbaud (BLKB) shares have seen some ups and downs throughout the past month, leaving investors weighing the company’s recent moves and long-term outlook. As volatility affects the tech sector, many are observing how Blackbaud adjusts its strategies. See our latest analysis for Blackbaud. Blackbaud has experienced a challenging stretch lately, with a 1-day share price return of 2.79% offering a brief bounce amid a broader trend of declining momentum. Over the past year, total shareholder...
NYSE:CIEN
NYSE:CIENCommunications

AI-Driven Revenue Surge Could Be a Game Changer for Ciena (CIEN)

Ciena reported third-quarter 2025 revenue of US$1.22 billion, surpassing its guidance and marking strong sequential and year-over-year growth as AI-driven infrastructure demand surged. Management signaled accelerated operating margin targets and highlighted record orders, reflecting Ciena’s strengthened position as AI adoption drives bandwidth and network expansion needs. We’ll explore how robust AI infrastructure demand shapes Ciena’s investment narrative following its standout revenue...
NasdaqGS:CCC
NasdaqGS:CCCSoftware

Did Q3 Results and EvolutionIQ Integration Just Shift CCC Intelligent Solutions Holdings' (CCC) Investment Narrative?

CCC Intelligent Solutions Holdings Inc. recently announced its Q3 2025 results, exceeding revenue estimates while highlighting ongoing challenges from lower claims volumes and integration of the EvolutionIQ acquisition. Despite consolidating operations and increasing share buybacks to offset high stock-based compensation, the company continues to trade at a premium valuation amid slower growth and reduced retention rates. We will explore how the continued operational challenges and...
NasdaqGS:COGT
NasdaqGS:COGTBiotechs

Why Cogent Biosciences (COGT) Is Up 18.9% After Positive Phase 3 GIST Trial Results

Cogent Biosciences recently announced positive results from its Phase 3 PEAK trial, showing that bezuclastinib combined with sunitinib significantly improved progression-free survival for gastrointestinal stromal tumor (GIST) patients resistant or intolerant to imatinib. The company plans to submit a new drug application to the FDA for bezuclastinib in GIST during the first half of 2026, highlighting its potential as a new second-line treatment standard. We'll explore how the successful...
NasdaqGS:PWP
NasdaqGS:PWPCapital Markets

Perella Weinberg (PWP): Assessing Current Valuation After Modest Share Price Uptick

Perella Weinberg Partners (PWP) shares moved slightly higher to start the week, climbing 2% in today’s session. Investors have been weighing the firm’s recent performance as broader market momentum shapes sentiment through the month. See our latest analysis for Perella Weinberg Partners. PWP’s 2% climb today is a bright spot, yet over the past year its share price return has been under pressure. While investors saw a sharp rally just a couple of years ago, momentum has cooled, with the 1-year...
NasdaqGS:UPWK
NasdaqGS:UPWKProfessional Services

Will Upwork (UPWK) Unlock Sustainable Growth Through International Expansion and AI Ambitions?

Upwork Inc. recently announced plans to open its first international operational hub in Lisbon, Portugal, with the office set to become fully operational in late 2026 and focused on product development and technical hiring. This move signals Upwork’s push to expand its footprint and capabilities outside the U.S., coinciding with new analyst optimism around its AI-driven growth strategy and increased market visibility due to upcoming index inclusion. We’ll now explore how Upwork’s...
NYSE:QS
NYSE:QSAuto Components

Why QuantumScape (QS) Is Down 8.6% After Evercore Downgrade and Commercialization Concerns

Shares of QuantumScape came under pressure after Evercore ISI downgraded the solid-state battery developer, citing challenges in market share expectations and partnership timelines following its recent symposium in Kyoto, Japan. Even with new institutional interest and strong liquidity highlighted by continued partnership billings and a recent capital raise, the company's path to commercialization remains under close watch from analysts and investors alike. We'll explore how ongoing...
NYSE:ZTS
NYSE:ZTSPharmaceuticals

Zoetis (ZTS): Reassessing Valuation as Market Optimism Follows Fed Rate Cut Comments

Zoetis (ZTS) popped 5% after a Federal Reserve official hinted that interest rate cuts could be on the table. This sparked optimism throughout the broader market and lifted shares despite limited direct business news for the company. See our latest analysis for Zoetis. Despite a wave of optimism from Fed comments, Zoetis’s 1-day share price return of 4.09% and 7-day rally have not reversed its broader downtrend. The company has a year-to-date share price return of -21.35% and a 1-year total...
NYSE:VLTO
NYSE:VLTOCommercial Services

Why Veralto (VLTO) Is Up 5.8% After US$750 Million Buyback Announcement and Analyst Upgrade

Veralto Corporation recently announced that its Board of Directors authorized a share repurchase program of up to US$750 million, marking a significant capital return initiative. This buyback, paired with an analyst upgrade reflecting improved earnings estimates, underscores growing market confidence in Veralto’s business outlook and strategy. We’ll examine how the sizeable US$750 million buyback authorization may influence Veralto’s investment narrative and future prospects. Find companies...
NasdaqGS:ZBIO
NasdaqGS:ZBIOBiotechs

Can Zenas BioPharma's (ZBIO) Improving Loss Per Share Shift Investor Confidence in Its Long-Term Story?

Zenas BioPharma, Inc. reported its third quarter and nine-month results for the period ended September 30, 2025, disclosing a net loss of US$51.5 million for the quarter and US$137.3 million over nine months, with nine-month revenue of US$10 million. While the company's net loss increased year-over-year, the basic loss per share from continuing operations improved significantly compared to the same periods in 2024. We'll explore how the narrower loss per share, despite higher net losses,...
NYSE:KBR
NYSE:KBRProfessional Services

Does KBR’s (KBR) Revenue Cut Shift the Long-Term Growth Narrative Amid Strategic Tech Moves?

In recent developments, KBR revised its 2025 revenue guidance downward by about US$900 million, primarily due to the exclusion of the HomeSafe JV revenue, while continuing progress on advanced product testing for NASA's Artemis III spacesuit and collaborating with Hazer Group and EnergyPathways on a nationally significant UK hydrogen and graphite project. This combination of a material financial guidance change alongside technology milestones and clean energy partnerships highlights the...
NYSE:MET
NYSE:METInsurance

MetLife (MET): Assessing Valuation After Recent Modest Share Price Movement

MetLife (MET) shares saw modest movement this week, giving investors a chance to review where the company stands after recent market shifts. The stock has tracked lower over the past month, inviting some fresh scrutiny. See our latest analysis for MetLife. While MetLife shares have drifted slightly lower over the last month, this fits into a broader picture of momentum fading after a strong multi-year run. The 1-year total shareholder return comes in at -11.2%, but looking further back, the...
NasdaqGM:IRMD
NasdaqGM:IRMDMedical Equipment

Assessing IRADIMED (IRMD) Valuation After Notable Share Price Gains in 2024

IRADIMED (IRMD) shares have caught the eye of investors recently, building on a solid stretch of gains. The company’s stock is up 17% over the past month and has climbed 68% so far this year. This reflects sustained interest in its performance. See our latest analysis for IRADIMED. After such a confident run, IRADIMED’s momentum is hard to miss. The share price has steadily advanced, with a 17% jump over the past month highlighting renewed optimism. Looking further back, its one-year total...
NYSE:DY
NYSE:DYConstruction

A Look at Dycom Industries’s Valuation Following Raised Revenue Outlook and Strong Quarterly Growth

Dycom Industries (DY) just posted another strong quarter, with both sales and net income showing meaningful increases compared to last year. In addition to these results, the company raised its full-year revenue outlook. See our latest analysis for Dycom Industries. Momentum has been building fast for Dycom Industries, especially after its earnings beat and higher revenue outlook. The stock turned heads with a 17.6% share price gain over the past week and a standout 97.2% year-to-date price...